=Carlisle (CSL) reported earnings on Tue 22 Oct 2019 (a/h)

Carlisle Cos beats by $0.11, reports revs in-line 

Reports Q3 (Sep) earnings of $2.40 per share, excluding non-recurring items, $0.11 better than the S&P Capital IQ Consensus of $2.29; revenues rose 8.4% year/year to $1.28 bln vs the $1.29 bln S&P Capital IQ Consensus.

• Organic Revenue growth of 3.4%

At CIT, despite 737 MAX 8 issues at Boeing, the aerospace environment is strong and backlog at major OEMs remains at record levels. Additionally, the Medical Technology markets remain robust, continuing to reflect the needs of an aging population and increased preference for minimally invasive surgical procedures. However, throughout the year we have seen increasingly negative impact on the global economy related to indecision and uncertainty produced by a failure to resolve both Brexit and the U.S./China trade negotiations. Late in the second quarter, we began to feel the effects in our most global businesses, CFT and CBF, which accelerated into the third quarter. Having delivered 3.4% third quarter organic growth in this environment, we remain optimistic that meaningful progress toward resolution would bolster confidence in global economies and provide fuel for growth in the near-term, assisting us in driving our Vision 2025 goals of 5% organic growth.